Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, et al. Graves’ disease. Nat Rev Dis Primers. 2020;6(1):52.
Smith TJ, Hegedus L. Graves’ Disease. N Engl J Med. 2016;375(16):1552–65.
Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003–2005. Clin Endocrinol (Oxf). 2013;78(5):768–76.
Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):923–31.
Cramon P, Winther KH, Watt T, Bonnema SJ, Bjorner JB, Ekholm O, et al. Quality-of-Life Impairments Persist Six Months After Treatment of Graves’ Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study. Thyroid. 2016;26(8):1010–8.
Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86.
Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.
Beshyah SA, Khalil AB, Sherif IH, Benbarka MM, Raza SA, Hussein W, et al. A Survey of Clinical Practice Patterns in Management of Graves Disease in the Middle East and North Africa. Endocr Pract. 2017;23(3):299–308.
Kornelius E, Yang YS, Huang CN, Wang YH, Lo SC, Lai YR, et al. The Trends of Hyperthyroidism Treatment in Taiwan: A Nationwide Population-Based Study. Endocr Pract. 2018;24(6):573–9.
Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–35.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–421.
Thyroid disease: assessment and management. National Institute for Health and Care Excellence. London: Clinical Guidelines; 2019.
Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Ospina NS, Maraka S, Dean DS, et al. Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves’ Disease. Thyroid. 2015;25(11):1191–8.
Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS, Maraka S, Tamhane S, Montori VM, et al. Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol. 2016;4(8):706–16.
Sriphrapradang C. Diagnosis and Management of Graves’ Disease in Thailand: A Survey of Current Practice. J Thyroid Res. 2020;2020:8175712.
Thewjitcharoen Y, Karndumri K, Chatchomchuan W, Porramatikul S, Krittiyawong S, Wanathayanoroj E, et al. Practice patterns and outcomes in the management of Thai patients with Graves’ disease. Thyroid Res. 2021;14(1):5.
Brito JP, Payne S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves’ Disease: A Nationwide Population-Based Study. Thyroid. 2020;30(3):357–64.
Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative Effectiveness of Treatment Choices for Graves’ Hyperthyroidism: A Historical Cohort Study. Thyroid. 2017;27(4):497–505.
Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671–7.
Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine doses for Graves disease treatment. Clin Nucl Med. 2012;37(3):241–4.
Azizi F. Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience. Thyroid. 2020;30(10):1451–7.
Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS. Outcomes in Relapsed Graves’ Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. Thyroid. 2015;25(12):1282–90.
Chahardahmasumi E, Salehidoost R, Amini M, Aminorroaya A, Rezvanian H, Kachooei A, et al. Assessment of the Early and Late Complication after Thyroidectomy. Adv Biomed Res. 2019;8:14.
Shinall MC Jr, Broome JT, Nookala R, Shinall JB, Kiernan C, Parks L 3rd, et al. Total thyroidectomy for Graves’ disease: compliance with American Thyroid Association guidelines may not always be necessary. Surgery. 2013;154(5):1009–15.
Sung TY, Lee YM, Yoon JH, Chung KW, Hong SJ. Long-Term Effect of Surgery in Graves’ Disease: 20 Years Experience in a Single Institution. Int J Endocrinol. 2015;2015:542641.
Rubio GA, Koru-Sengul T, Vaghaiwalla TM, Parikh PP, Farra JC, Lew JI. Postoperative Outcomes in Graves’ Disease Patients: Results from the Nationwide Inpatient Sample Database. Thyroid. 2017;27(6):825–31.
Andersen SL, Olsen J, Laurberg P. Antithyroid Drug Side Effects in the Population and in Pregnancy. J Clin Endocrinol Metab. 2016;101(4):1606–14.
Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013;98(12):4776–83.
Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, Liu ZF, et al. Characteristics of Antithyroid Drug-Induced Agranulocytosis in Patients with Hyperthyroidism: A Retrospective Analysis of 114 Cases in a Single Institution in China Involving 9690 Patients Referred for Radioiodine Treatment Over 15 Years. Thyroid. 2016;26(5):627–33.
Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, et al. Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017;176(1):87–97.
Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves’ Hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381–9.